EUVIMEDEUVIMED entdecken
Crossref

Abstract 18344: Beyond Statins: Real-World Long-Term Effectiveness of PCSK9 Inhibitors versus Ezetimibe in Atherosclerotic Cardiovascular Disease

Umang Gupta, Suman Khanal, Krutagni Adwait Mehta, Ritu C. Tated, Shilpkumar Arora

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.18344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Umang Gupta und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of global morbidity and mortality.Although statins remain the foundation of lipid-lowering therapy, some patients need add-on agents such as ezetimibe or PCSK9 inhibitors to reach guideline LDL-C targets. However, real-world data comparing the long-term effectiveness of these two strategies are limited. Research Question: What are the long-term real-world outcomes of PCSK9 inhibitor-based versus ezetimibe-based regimens in patients with ASCVD on statin therapy?

Methods

Using the TriNetX Research Network, we identified patients with ASCVD on statin therapy prescribed ezetimibe (N=176,169) or a PCSK9 inhibitor (N=16,150). Propensity score matching generated two well-balanced cohorts (N=16,145 per group). Primary and secondary outcomes; all-cause mortality, all-cause readmission, myocardial infarction (MI), revascularization, major adverse cardiovascular events (MACE), ischemic stroke, and heart failure (HF) exacerbation-were analyzed over 3-year and 5-year follow-ups.

Results

Baseline mean low-density lipoprotein cholesterol was higher in the PCSK9 inhibitor group than the ezetimibe group (114.2±54.5 mg/dL vs 98.9±41.1 mg/dL). The PCSK9 inhibitor regimen demonstrated a significant reduction in all-cause mortality at 3 years (OR: 0.78, p

Zitieren

APA

Gupta, U., Khanal, S., Mehta, K. A., Tated, R. C., & Arora, S. (2026). Abstract 18344: Beyond Statins: Real-World Long-Term Effectiveness of PCSK9 Inhibitors versus Ezetimibe in Atherosclerotic Cardiovascular Disease. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.18344

Vancouver

Gupta U, Khanal S, Mehta KA, Tated RC, Arora S. Abstract 18344: Beyond Statins: Real-World Long-Term Effectiveness of PCSK9 Inhibitors versus Ezetimibe in Atherosclerotic Cardiovascular Disease. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.18344

BibTeX
@article{Gupta2026,
  author = {Gupta, Umang and Khanal, Suman and Mehta, Krutagni Adwait and Tated, Ritu C. and Arora, Shilpkumar},
  title = {Abstract 18344: Beyond Statins: Real-World Long-Term Effectiveness of PCSK9 Inhibitors versus Ezetimibe in Atherosclerotic Cardiovascular Disease},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.18344}
}
Kostenlos starten →